원료의약품(API) 시장(2026-2030년)

The global active pharmaceutical ingredients market is forecasted to grow by USD 105407.0 mn during 2025-2030, accelerating at a CAGR of 7.2% during the forecast period. The report on the global active pharmaceutical ingredients market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by heightened harmonization and mandatory supply chain traceability frameworks, escalating global burden of chronic diseases and advanced biologics, exponential of generic and biosimilar sector driven by blockbuster patent expirations.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global active pharmaceutical ingredients market is segmented as below:

By Manufacturing Type

• Captive APIs
• Contract APIs

By Type

• Innovative APIs
• Generic APIs

By Application

• Cardiovascular diseases
• Oncology
• CNS and neurology
• Orthopedic
• Others

Geography

• Asia
• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • The Netherlands
  • Spain
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the surging demand for biologics and highly potent active pharmaceutical ingredients as one of the prime reasons driving the global active pharmaceutical ingredients market growth during the next few years. Also, supply chain reshoring and strategic geographic diversification and rapid adoption of continuous manufacturing and digital automation will lead to sizable demand in the market.

The report on the global active pharmaceutical ingredients market covers the following areas:

• Global active pharmaceutical ingredients market sizing
• Global active pharmaceutical ingredients market forecast
• Global active pharmaceutical ingredients market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global active pharmaceutical ingredients market vendors that include Alembic Pharmaceuticals Ltd., Aurobindo Pharma Ltd., BASF SE, Boehringer Ingelheim GmbH, Cambrex Corp., Cipla Inc., Corden Pharma Intl. GmbH, Curia Global Inc., Dipharma Francis S.r.l., Divis Laboratories Ltd., Dr. Reddys Laboratories Ltd., EUROAPI S.A., Evonik Industries AG, Jubilant Pharmova Ltd., Lonza Group Ltd., Lupin Ltd., Neuland Laboratories, Siegfried Holding AG, Sun Pharmaceutical Industries, Teva Pharmaceutical Ltd.. Also, the global active pharmaceutical ingredients market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Manufacturing Type
  • Executive Summary - Chart on Market Segmentation by Type
  • Executive Summary - Chart on Market Segmentation by Application
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Active Pharmaceutical Ingredients Market 2020 - 2024
  • Historic Market Size - Data Table on Global Active Pharmaceutical Ingredients Market 2020 - 2024 ($ million)
• 5.2 Manufacturing Type segment analysis 2020 - 2024
  • Historic Market Size - Manufacturing Type Segment 2020 - 2024 ($ million)
• 5.3 Type segment analysis 2020 - 2024
  • Historic Market Size - Type Segment 2020 - 2024 ($ million)
• 5.4 Application segment analysis 2020 - 2024
  • Historic Market Size - Application Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on Global Active Pharmaceutical Ingredients Market
• 6.2 Impact of geopolitical conflicts on Global Active Pharmaceutical Ingredients Market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Manufacturing Type

• 8.1 Market segments
• 8.2 Comparison by Manufacturing Type
• 8.3 Captive APIs - Market size and forecast 2025-2030
• 8.4 Contract APIs - Market size and forecast 2025-2030
• 8.5 Market opportunity by Manufacturing Type
  • Market opportunity by Manufacturing Type ($ million)

9 Market Segmentation by Type

• 9.1 Market segments
• 9.2 Comparison by Type
• 9.3 Innovative APIs - Market size and forecast 2025-2030
• 9.4 Generic APIs - Market size and forecast 2025-2030
• 9.5 Market opportunity by Type
  • Market opportunity by Type ($ million)

10 Market Segmentation by Application

• 10.1 Market segments
• 10.2 Comparison by Application
• 10.3 Cardiovascular diseases - Market size and forecast 2025-2030
• 10.4 Oncology - Market size and forecast 2025-2030
• 10.5 CNS and neurology - Market size and forecast 2025-2030
• 10.6 Orthopedic - Market size and forecast 2025-2030
• 10.7 Others - Market size and forecast 2025-2030
• 10.8 Market opportunity by Application
  • Market opportunity by Application ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 Asia - Market size and forecast 2025-2030
  • 12.3.1 China - Market size and forecast 2025-2030
  • 12.3.2 India - Market size and forecast 2025-2030
  • 12.3.3 Japan - Market size and forecast 2025-2030
  • 12.3.4 South Korea - Market size and forecast 2025-2030
  • 12.3.5 Thailand - Market size and forecast 2025-2030
  • 12.3.6 Indonesia - Market size and forecast 2025-2030
• 12.4 North America - Market size and forecast 2025-2030
  • 12.4.1 US - Market size and forecast 2025-2030
  • 12.4.2 Canada - Market size and forecast 2025-2030
  • 12.4.3 Mexico - Market size and forecast 2025-2030
• 12.5 Europe - Market size and forecast 2025-2030
  • 12.5.1 Germany - Market size and forecast 2025-2030
  • 12.5.2 UK - Market size and forecast 2025-2030
  • 12.5.3 France - Market size and forecast 2025-2030
  • 12.5.4 Italy - Market size and forecast 2025-2030
  • 12.5.5 The Netherlands - Market size and forecast 2025-2030
  • 12.5.6 Spain - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Brazil - Market size and forecast 2025-2030
  • 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.3 Turkey - Market size and forecast 2025-2030
  • 12.6.4 UAE - Market size and forecast 2025-2030
  • 12.6.5 Argentina - Market size and forecast 2025-2030
  • 12.6.6 South Africa - Market size and forecast 2025-2030
  • 12.6.7 Colombia - Market size and forecast 2025-2030
  • 12.6.8 Israel - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Heightened harmonization and mandatory supply chain traceability frameworks
  • Escalating global burden of chronic diseases and advanced biologics
  • Exponential of generic and biosimilar sector driven by blockbuster patent expirations
• 13.2 Market challenges
  • Geopolitical reshoring pressures and complex supply chain disruption
  • Severe margin pressures in generic chemical manufacturing and pricing controls
  • Navigating fragmented international regulatory harmonization and quality auditing
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Surging demand for biologics and highly potent active pharmaceutical ingredients
  • Supply chain reshoring and strategic geographic diversification
  • Rapid adoption of continuous manufacturing and digital automation

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 Alembic Pharmaceuticals Ltd.
  • Alembic Pharmaceuticals Ltd. - Overview
  • Alembic Pharmaceuticals Ltd. - Product / Service
  • Alembic Pharmaceuticals Ltd. - Key offerings
  • SWOT
• 15.5 Aurobindo Pharma Ltd.
  • Aurobindo Pharma Ltd. - Overview
  • Aurobindo Pharma Ltd. - Business segments
  • Aurobindo Pharma Ltd. - Key news
  • Aurobindo Pharma Ltd. - Key offerings
  • Aurobindo Pharma Ltd. - Segment focus
  • SWOT
• 15.6 BASF SE
  • BASF SE - Overview
  • BASF SE - Business segments
  • BASF SE - Key news
  • BASF SE - Key offerings
  • BASF SE - Segment focus
  • SWOT
• 15.7 Cipla Inc.
  • Cipla Inc. - Overview
  • Cipla Inc. - Business segments
  • Cipla Inc. - Key news
  • Cipla Inc. - Key offerings
  • Cipla Inc. - Segment focus
  • SWOT
• 15.8 Divis Laboratories Ltd.
  • Divis Laboratories Ltd. - Overview
  • Divis Laboratories Ltd. - Product / Service
  • Divis Laboratories Ltd. - Key offerings
  • SWOT
• 15.9 Dr. Reddys Laboratories Ltd.
  • Dr. Reddys Laboratories Ltd. - Overview
  • Dr. Reddys Laboratories Ltd. - Business segments
  • Dr. Reddys Laboratories Ltd. - Key news
  • Dr. Reddys Laboratories Ltd. - Key offerings
  • Dr. Reddys Laboratories Ltd. - Segment focus
  • SWOT
• 15.10 EUROAPI S.A.
  • EUROAPI S.A. - Overview
  • EUROAPI S.A. - Product / Service
  • EUROAPI S.A. - Key offerings
  • SWOT
• 15.11 Evonik Industries AG
  • Evonik Industries AG - Overview
  • Evonik Industries AG - Business segments
  • Evonik Industries AG - Key offerings
  • Evonik Industries AG - Segment focus
  • SWOT
• 15.12 Jubilant Pharmova Ltd.
  • Jubilant Pharmova Ltd. - Overview
  • Jubilant Pharmova Ltd. - Business segments
  • Jubilant Pharmova Ltd. - Key offerings
  • Jubilant Pharmova Ltd. - Segment focus
  • SWOT
• 15.13 Lonza Group Ltd.
  • Lonza Group Ltd. - Overview
  • Lonza Group Ltd. - Business segments
  • Lonza Group Ltd. - Key offerings
  • Lonza Group Ltd. - Segment focus
  • SWOT
• 15.14 Lupin Ltd.
  • Lupin Ltd. - Overview
  • Lupin Ltd. - Business segments
  • Lupin Ltd. - Key news
  • Lupin Ltd. - Key offerings
  • Lupin Ltd. - Segment focus
  • SWOT
• 15.15 Neuland Laboratories
  • Neuland Laboratories - Overview
  • Neuland Laboratories - Product / Service
  • Neuland Laboratories - Key offerings
  • SWOT
• 15.16 Siegfried Holding AG
  • Siegfried Holding AG - Overview
  • Siegfried Holding AG - Business segments
  • Siegfried Holding AG - Key offerings
  • Siegfried Holding AG - Segment focus
  • SWOT
• 15.17 Sun Pharmaceutical Industries
  • Sun Pharmaceutical Industries - Overview
  • Sun Pharmaceutical Industries - Business segments
  • Sun Pharmaceutical Industries - Key news
  • Sun Pharmaceutical Industries - Key offerings
  • Sun Pharmaceutical Industries - Segment focus
  • SWOT
• 15.18 Teva Pharmaceutical Ltd.
  • Teva Pharmaceutical Ltd. - Overview
  • Teva Pharmaceutical Ltd. - Business segments
  • Teva Pharmaceutical Ltd. - Key news
  • Teva Pharmaceutical Ltd. - Key offerings
  • Teva Pharmaceutical Ltd. - Segment focus
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations